Dr. Leigh Perreault is a physician and clinical researcher at the University of Colorado Denver School of Medicine, Aurora, CO. Her overarching research interest lies in understanding the different pathways by which people develop type 2 diabetes, and developing tailored strategies for diabetes prevention. Research projects to date have yielded valuable information about sex differences in diabetes risk, which lie, in part, in the key metabolic features in people with different types of pre-diabetes (impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and IFG/IGT). Recently, research pursuits have focused on unraveling the pathophysiology underlying isolated IFG – a prominent type of pre-diabetes – affecting roughly 25 million Americans. Specific environmental pollutants are strongly implicated as causal in IFG, hence proposed projects are aimed at removing these in a research setting to see if normal glucose regulation can be restored. Complimenting her independent research interests, Dr. Perreault works closely with collaborators examining emerging risk factors for diabetes such as sleep restriction, intramuscular lipids and the human microbiome. Dr. Perreault is part of the Diabetes Prevention Program (DPP) and heavily utilizes the Clinical Translational Research Center (CTRC) on campus.
Dr. Perreault graduated from the University of Southern California Keck School of Medicine in 1996. She completed a residency in Internal Medicine and fellowship in Endocrinology, Metabolism and Diabetes at the University of Colorado Denver School of Medicine, and is currently board-certified in both. Dr. Perreault has received an Endocrine Fellow's Foundation Award, Patient-oriented Career Development Award (K23) from the National Institutes of Health, as well as a Career Development Award from the American Diabetes Association, for her work unraveling the metabolic complexities of pre-diabetes. She works tirelessly on behalf of people at risk for diabetes, both as a volunteer for the American Diabetes Association, a national and internal educator, and directly through clinical care of people with pre-diabetes and diabetes.
Click here to see her recent interview at the American Diabetes Association 72nd Scientific Sessions in Philadelphia.
- Faerch, K, Bergman BC, Perreault, L. Insulin resistance, not plasma glucose, drives cardiovascular disease risk in humans. PLoS One, in press 2012.
- Bergman BC, Perreault L, Hunerdosse, Kerege A, Playdon M, Samek AM, Eckel RH. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes, in press 2012.
- Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from pre-diabetes to normal glucose regulation on long-term reduction nn diabetes risk: Results from the Diabetes Prevention Program Outcomes Study. The Lancet, PUBMED
- Bergman BC, Howard D, Schauer IE, Maahs DM, Snell-Bergeon JK, Eckel RH, Perreault L, Rewers M.J Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes. Clin Endocrinol Metab. 2012 Feb 22. PUBMED
- Bergman BC, Hunerdosse DM, Kerege A, Playdon MC, Perreault L. Localisation and composition of skeletal muscle diacylglycerol predicts insulin resistance in humans. Diabetologia, 2012 Apr; 55(4):1140-50. PUBMED
- Florez H, Ma Y, Crandall JP, Perreault L, Marcovina SM, Bray GA, Saudek CD, Barrett-Connor E, Knowler WC. Parental longevity and diabetes risk in the Diabetes Prevention Program. Gerontol A Biol Sci Med Sci. 2011 Nov;66(11):1211-7. PUBMED
- Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E; Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause. 2011 Aug;18(8):857-68. PUBMED
- Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S; DIAGRAM Consortium, Meigs JB, Altshuler D, WC, Florez JC; Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes Prevention Program Research Group. Diabetes. 2011 Apr;60(4):1340-8. Epub 2011 Mar 4. PUBMED
- Perreault L, Bergman BC, Hunerdosse DM, Howard DJ, Eckel RH. Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. Metabolism. 2011 Aug;60(8):1107-14. Epub 2011 Feb 8. PUBMED
- Perreault L, Man CD, Hunerdosse DM, Cobelli C, Bergman BC. Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.
Diabetes Res Clin Pract. 2010 Oct;90(1):87-94. Epub 2010 Aug 13. PUBMED
- Diabetes Prevention and Care